The global DNA repair drugs market size accounted for US$ 7.15 billion in 2023 and is projected to reach around USD 27.45 billion by 2033, growing at a CAGR of 14.40% from 2024 to 2033.
Key Points
- North America dominated the DNA repair drugs market in 2023.
- Asia Pacific is projected to emerge as a significant player in the market.
- By product type, the PARP inhibitors segment held the largest share of the market in 2023.
- By product type, the ATM kinase segment is expected to witness the fastest growth during the forecast period.
- By application type, the cancer therapy segment held the dominating share of the market in 2023.
- By application type, the genetic disorders commercial consumers segment is observed to witness a significant rate of expansion during the forecast period.
- By distribution channel, the hospital pharmacies segment held a significant share of the in 2023.
- By distribution channel, the specialty clinics segment is projected to experience substantial growth in the coming years.
Report Summary
The global DNA repair drugs market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the DNA repair drugs market across the globe.
A comprehensive estimate on the DNA repair drugs market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of DNA repair drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3880
DNA Repair Drugs Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 14.40% |
| Global Market Size in 2023 | USD 7.15 Billion |
| Global Market Size by 2033 | USD 27.45 Billion |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Drug Type, By Application Type, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized DNA repair drugs market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Biophotonics Market Size to Cross USD 182.74 Billion by 2033
Market Players
The report includes the profiles of key DNA repair drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Recent Developments
- In June 2023, AstraZeneca introduced IMJUDO® (tremelimumab) in the UAE, pioneering cancer treatment in the Middle East. The groundbreaking medication heralds a new era in cancer therapy, offering hope to patients and positioning the UAE at the forefront of medical innovation in the region.
- In June 2023, the University of Saskatchewan (USask) initiated a pioneering clinical trial to enhance ovarian cancer treatment, setting a global precedent. This innovative approach not only promises to enhance patients’ quality of life but also aims to streamline clinical practices and reduce healthcare costs associated with ovarian cancer management.
DNA Repair Drugs Market Companies
- Abbvie Inc.
- Amgen Inc.
- Abbott
- Astrazeneca Plc
- Bayer Ag
- Bristol-Myers Squibb Co.
- Eli Lilly And Co.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Gsk Plc.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Merck Kgaa
- Novartis Ag
- Pfizer Inc.
- Sanofi
Segment Covered in the Report
By Drug Type
- PARP Inhibitors
- ATM Kinase Inhibitors
- ATR Inhibitors
- DNA-PK Inhibitors
- BER Inhibitors
- NER Inhibitors
- Mismatch Repair (MMR) Inhibitors
- Homologous Recombination (HR) Inhibitors
- Non-Homologous End Joining (NHEJ) Inhibitors
By Application Type
- Cancer Therapy
- Genetic Disorders
- Neurodegenerative Diseases
- Immune Deficiencies
- Rare Genetic Syndromes
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on DNA Repair Drugs Market
5.1. COVID-19 Landscape: DNA Repair Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global DNA Repair Drugs Market, By Drug Type
8.1. DNA Repair Drugs Market, by Drug Type, 2024-2033
8.1.1 PARP Inhibitors
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. ATM Kinase Inhibitors
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. ATR Inhibitors
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. DNA-PK Inhibitors
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. BER Inhibitors
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. NER Inhibitors
8.1.6.1. Market Revenue and Forecast (2021-2033)
8.1.7. Mismatch Repair (MMR) Inhibitors
8.1.7.1. Market Revenue and Forecast (2021-2033)
8.1.8. Homologous Recombination (HR) Inhibitors
8.1.8.1. Market Revenue and Forecast (2021-2033)
8.1.9. Non-Homologous End Joining (NHEJ) Inhibitors
8.1.9.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global DNA Repair Drugs Market, By Application Type
9.1. DNA Repair Drugs Market, by Application Type, 2024-2033
9.1.1. Cancer Therapy
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Genetic Disorders
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Neurodegenerative Diseases
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Immune Deficiencies
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Rare Genetic Syndromes
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global DNA Repair Drugs Market, By Distribution Channel
10.1. DNA Repair Drugs Market, by Distribution Channel, 2024-2033
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Specialty Clinics
10.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global DNA Repair Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.2.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.3.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.4.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.5.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Application Type (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
Chapter 12. Company Profiles
12.1. Abbvie Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Amgen Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Abbott
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Astrazeneca Plc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer Ag
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bristol-Myers Squibb Co.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Eli Lilly And Co.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. F. Hoffmann-La Roche Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Gilead Sciences Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Gsk Plc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
